Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $172.6 million.

  • Relay Therapeutics' Shares Outstanding rose 344.22% to $172.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.6 million, marking a year-over-year increase of 344.22%. This contributed to the annual value of $167.8 million for FY2024, which is 3161.19% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Shares Outstanding is $172.6 million, which was up 344.22% from $171.7 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Shares Outstanding registered a high of $172.6 million during Q3 2025, and its lowest value of $90.4 million during Q1 2021.
  • For the 5-year period, Relay Therapeutics' Shares Outstanding averaged around $129.1 million, with its median value being $121.9 million (2023).
  • Per our database at Business Quant, Relay Therapeutics' Shares Outstanding tumbled by 5747.4% in 2021 and then skyrocketed by 3550.28% in 2024.
  • Quarter analysis of 5 years shows Relay Therapeutics' Shares Outstanding stood at $108.2 million in 2021, then increased by 11.92% to $121.1 million in 2022, then grew by 5.24% to $127.5 million in 2023, then skyrocketed by 31.61% to $167.8 million in 2024, then grew by 2.91% to $172.6 million in 2025.
  • Its Shares Outstanding was $172.6 million in Q3 2025, compared to $171.7 million in Q2 2025 and $170.5 million in Q1 2025.